Retina Screenings May Detect Alzheimer’s
July 15th, 2014 by Carolina Eye Associates
Reviewed by John M. Grohol, Psy.D. on July 13, 2014
Preliminary findings suggest noninvasive optical imaging can provide early detection of changes associated with Alzheimer’s disease.
The discovery was made by investigators conducting a clinical trial in Australia and will be reported at the Alzheimer’s Association International Conference 2014 in Copenhagen, Denmark.
“In preliminary results in 40 patients, the test could differentiate between Alzheimer’s disease and non-Alzheimer’s disease with 100 percent sensitivity and 80.6 percent specificity, meaning that all people with the disease tested positive and most of the people without the disease tested negative.”
The optical imaging exam appears to detect changes that occur 15-20 years before clinical diagnosis.
“It’s a practical exam that could allow testing of new therapies at an earlier stage, increasing our chances of altering the course of Alzheimer’s disease,” said Shaun Frost, a biomedical scientist and the study manager.
Keith Black, M.D., professor and chair of Cedars-Sinai’s Department of Neurosurgery said the accumulation of beta-amyloid plaque in the brain is a hallmark sign of Alzheimer’s, but current tests detect changes only after the disease has advanced to late stages.
Researchers believe that as treatment options improve, early detection will be critical, but existing diagnostic methods are inconvenient, costly, and impractical for routine screening.
“PET scans require the use of radioactive tracers, and cerebrospinal fluid analysis requires that patients undergo invasive and often painful lumbar punctures, but neither approach is quite feasible, especially for patients in the earlier stages of disease,” he said.
Positron emission tomography, or PET, is the current diagnostic standard.
“The retina, unlike other structures of the eye, is part of the central nervous system, sharing many characteristics of the brain. A few years ago, we discovered at Cedars-Sinai that the plaques associated with Alzheimer’s disease occur not only in the brain but also in the retina.
“By ‘staining’ the plaque with curcumin, a component of the common spice turmeric, we could detect it in the retina even before it began to accumulate in the brain.
“The device we developed enables us to look through the eye — just as an ophthalmologist looks through the eye to diagnose retinal disease — and see these changes.”
This clinical trial was designed to enable researchers to correlate retinal plaque detected by optical imaging with brain plaque detected by PET scans. Studies involved patients diagnosed with Alzheimer’s, a group with mild cognitive impairment, and a group of people with no evidence of brain abnormality.
The retinal beta-amyloid plaque findings and optical imaging technology began at Cedars-Sinai with studies in live rodents and the post-mortem investigation of human retinas of people who had died with Alzheimer’s.
The Australian study is one of several in progress to determine if similar results can be confirmed in humans living with the disease.
“This large double-blind clinical trial appears to validate our novel human retinal amyloid imaging approach using curcumin labeling.
“It further demonstrates significant correlation with brain amyloid burden, thereby predicting accumulation of plaques in the brain through the retina,” said Maya Koronyo-Hamaoui, Ph.D, a faculty principal investigator at Cedars-Sinai.
Source: Cedars-Sinai Medical Center
Comments are closed.